

Trivadi Ganesan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4632128/publications.pdf>

Version: 2024-02-01

126
papers

4,119
citations

145106

33
h-index

150775

59
g-index

126
all docs

126
docs citations

126
times ranked

5075
citing authors

#	ARTICLE	IF	CITATIONS
1	LASP-1 interacts with ErbB2 in ovarian cancer cells. <i>Biochemical Journal</i> , 2022, 479, 23-38.	1.7	1
2	Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2022, 1870, 140768.	1.1	3
3	Haploidentical Hematopoietic Stem Cell Transplantation in Leukemiaâ€™s: Experience from a Cancer Center in India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 463-471.	0.3	6
4	Autologous Stem Cell Transplantation in Testicular Germ Cell Tumorâ€™ Preliminary Experience from a Single Center. <i>South Asian Journal of Cancer</i> , 2021, 10, 97-101.	0.2	1
5	Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. <i>JCO Global Oncology</i> , 2021, 7, 767-781.	0.8	15
6	Development and in vitro characterisation of an induced pluripotent stem cell model of ovarian cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 138, 106051.	1.2	9
7	Development of a Critical Appraisal Tool (AIMRDA) for the Peer-Review of Studies Assessing the Anticancer Activity of Natural Products: A Step towards Reproducibility. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3735-3740.	0.5	1
8	â€™Hairy Cell Leukemia (HCL): â€™Real Worldâ€™ Outcomeâ€™. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 267-270.	0.3	0
9	Malnutrition is a predisposing factor for developing recurrent fever following febrile neutropenia in children with acute lymphoblastic leukemia. <i>Pediatric Hematology Oncology Journal</i> , 2020, 5, 75-79.	0.1	3
10	The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 601-616.	2.1	23
11	Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapyâ€™induced vomiting in children: An openâ€™label, randomized phase 3 trial. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28532.	0.8	17
12	Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. <i>Cancer Biomarkers</i> , 2020, 28, 397-408.	0.8	12
13	Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkinâ€™s lymphoma. <i>Leukemia Research</i> , 2019, 84, 106188.	0.4	8
14	Analysis of Human Stem Cell Transcription Factors. <i>Cellular Reprogramming</i> , 2019, 21, 171-180.	0.5	12
15	Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. <i>Angiogenesis</i> , 2019, 22, 441-455.	3.7	19
16	Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 640-648.	0.3	5
17	Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India. <i>Indian Journal of Pediatrics</i> , 2019, 86, 417-426.	0.3	6
18	Analysis of hematopoietic stem cells using a composite approach. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 109, 82-89.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Induced pluripotent stem cells: A new strategy to model human cancer. International Journal of Biochemistry and Cell Biology, 2019, 107, 62-68.	1.2	17
20	Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial. Pediatric Blood and Cancer, 2019, 66, e27551.	0.8	18
21	Abstract 182: Cancer stem cells and tumor angiogenesis in serous adenocarcinoma of ovary. , 2019, , .		3
22	Abstract 3693: GLIS1 can replace MYC to generate induced pluripotent stem cells from ovarian cancer cells. , 2019, , .		0
23	Efficacy of Single Dose Rasburicase (1.5Âmg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 618-622.	0.3	6
24	Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. Indian Heart Journal, 2018, 70, 319-322.	0.2	5
25	Prevalence of multi-drug resistant organisms in stool of paediatric patients with acute leukaemia and correlation with blood culture positivity: A single institution experience. Pediatric Blood and Cancer, 2018, 65, e26740.	0.8	15
26	A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. Biochemistry and Cell Biology, 2018, 96, 295-305.	0.9	16
27	Pediatric Nonblastic Non-Hodgkin's Lymphoma: A Perspective from India. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 13-17.	0.1	6
28	Therapeutic antibodies against cancer stem cells: a promising approach. Cancer Immunology, Immunotherapy, 2017, 66, 1383-1398.	2.0	12
29	Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance. International Journal of Clinical Oncology, 2017, 22, 107-117.	1.0	14
30	Chemotherapy in carcinoma penis: Experience from a tertiary cancer centre in India. Annals of Oncology, 2017, 28, x83.	0.6	2
31	Short-Course Lenalidomide Plus Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma—A Single-Centre Pragmatic Study. Current Oncology, 2017, 24, 361-367.	0.9	1
32	Refractory Choriocarcinoma: Complete Response With Oral Etoposide. Journal of Global Oncology, 2017, 3, 678-679.	0.5	2
33	Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget, 2017, 8, 7521-7532.	0.8	37
34	Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. Indian Journal of Cancer, 2017, 54, 430.	0.2	9
35	Abstract 4200: Targeting cancer stem cells in serous ovarian carcinoma using RP6530, a dual PI3k γ / δ inhibitor. , 2017, , .		0
36	Tumour angiogenesis—Origin of blood vessels. International Journal of Cancer, 2016, 139, 729-735.	2.3	102

#	ARTICLE	IF	CITATIONS
37	Increasing incidence of multidrug-resistant Gram-negative septicaemia during induction therapy of acute Myeloid leukaemia. <i>Journal of Hospital Infection</i> , 2016, 93, 314-315.	1.4	11
38	Acute Myeloid Leukemia in Children: Experience from Tertiary Cancer Centre in India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 257-261.	0.3	14
39	Cancer Stem Cells – Are Surface Markers Alone Sufficient?. <i>Current Stem Cell Research and Therapy</i> , 2016, 12, 37-44.	0.6	25
40	Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 53-58.	0.1	8
41	A novel mathematical approach to predict outcome in adult Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19016-e19016.	0.8	0
42	Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1170-1174.	0.6	35
43	Gemcitabine, Vinorelbine and Dexamethasone (GVDexa) As Second-Line Salvage Regimen in Relapsed and Refractory Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 3948-3948.	0.6	2
44	Nutritional profile of pediatric cancer patients at Cancer Institute, Chennai. <i>Indian Journal of Cancer</i> , 2015, 52, 207.	0.2	16
45	Acute lymphoblastic leukemia: A single center experience with Berlin, Frankfurt, and Munster-95 protocol. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 261-264.	0.1	23
46	P0011 Paediatric acute myeloid leukaemia experience in a tertiary cancer centre in southern India. <i>European Journal of Cancer</i> , 2014, 50, e12.	1.3	0
47	Transformation of follicular lymphoma to high-grade Burkitt's like lymphoma and acute lymphoblastic leukemia-L3 type. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 136-137.	0.1	0
48	The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A. <i>Protein and Cell</i> , 2011, 2, 237-249.	4.8	9
49	A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. <i>British Journal of Cancer</i> , 2010, 102, 1355-1360.	2.9	129
50	Lichen planus associated with imatinib mesylate. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2009, 75, 527.	0.2	2
51	The tumour suppressor RASSF1A is a novel substrate of PKC. <i>FEBS Letters</i> , 2008, 582, 2270-2276.	1.3	19
52	A phase II study of low dose thalidomide and dexamethasone in previously untreated multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 19520-19520.	0.8	0
53	Role of Lymphangiogenesis in Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4298-4307.	0.8	132
54	RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. <i>Oncogene</i> , 2007, 26, 683-700.	2.6	92

#	ARTICLE	IF	CITATIONS
55	Role of lymphangiogenesis in epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2006, 94, 1650-1657.	2.9	27
56	Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2005, 93, 60-69.	2.9	5
57	Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5950-5959.	0.8	146
58	Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells. <i>Molecular Cell</i> , 2005, 20, 673-685.	4.5	96
59	Use of changes in CA125 doubling time to detect activity of cytostatic agents in women relapsing with ovarian carcinoma. Study 1 - tamoxifen. <i>Journal of Clinical Oncology</i> , 2005, 23, 5119-5119.	0.8	0
60	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6528-6534.	3.2	180
61	A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. <i>Clinical Cancer Research</i> , 2004, 10, 2986-2996.	3.2	76
62	Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2004, 91, 1645-1650.	2.9	20
63	Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. <i>British Journal of Cancer</i> , 2004, 91, 30-36.	2.9	33
64	Tyrosine kinase inhibitors in cancer therapy. <i>Clinical Biochemistry</i> , 2004, 37, 618-635.	0.8	197
65	A randomised trial of carboplatin versus carboplatin and thalidomide in ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. <i>Journal of Clinical Oncology</i> , 2004, 22, 5024-5024.	0.8	0
66	A phase 1 study of tazarotene in adults with advanced cancer. <i>British Journal of Cancer</i> , 2003, 89, 808-815.	2.9	11
67	Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. <i>British Journal of Cancer</i> , 2003, 89, 1166-1171.	2.9	45
68	Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000. <i>Journal of Clinical Oncology</i> , 2003, 21, 203-210.	0.8	39
69	Tumour suppressor genes in sporadic epithelial ovarian cancer. <i>Reproduction</i> , 2002, 123, 341-353.	1.1	21
70	RYK, a Catalytically Inactive Receptor Tyrosine Kinase, Associates with EphB2 and EphB3 but Does Not Interact with AF-6. <i>Journal of Biological Chemistry</i> , 2002, 277, 23037-23043.	1.6	41
71	Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. <i>Oncogene</i> , 2002, 21, 387-399.	2.6	26
72	Retrospective Study of Management of Uterine Sarcomas at Oxford 1990-1998: Role of Adjuvant Treatment. <i>Clinical Oncology</i> , 2002, 14, 54-61.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C. <i>Journal of Clinical Oncology</i> , 2001, 19, 1485-1492.	0.8	226
74	Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. <i>International Journal of Molecular Medicine</i> , 2001, 8, 405-12.	1.8	10
75	Evaluation of the Possible Protective Role of Adeno-Associated Virus Type 2 Infection in HPV-Associated Premalignant Disease of the Cervix. <i>Gynecologic Oncology</i> , 2000, 78, 342-345.	0.6	14
76	Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2000, 82, 1776-1782.	2.9	4
77	Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. <i>British Journal of Cancer</i> , 2000, 82, 1759-1763.	2.9	15
78	Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. <i>British Journal of Cancer</i> , 2000, 83, 219-224.	2.9	14
79	Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 27-34.	1.1	39
80	Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. <i>Clinical Cancer Research</i> , 2000, 6, 3271-81.	3.2	20
81	A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. <i>Clinical Cancer Research</i> , 2000, 6, 4697-704.	3.2	43
82	Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours. <i>Annals of Oncology</i> , 1999, 10, 923-927.	0.6	108
83	A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 1999, 10, 981-983.	0.6	5
84	Functional Analysis of H-Ryk, an Atypical Member of the Receptor Tyrosine Kinase Family. <i>Molecular and Cellular Biology</i> , 1999, 19, 6427-6440.	1.1	66
85	Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. <i>Cancer Research</i> , 1999, 59, 2265-70.	0.4	15
86	Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. <i>Clinical Cancer Research</i> , 1999, 5, 1682-9.	3.2	38
87	Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. <i>British Journal of Cancer</i> , 1998, 77, 1950-1956.	2.9	10
88	Chemotherapy for ovarian cancer - a consensus statement on standard practice. <i>British Journal of Cancer</i> , 1998, 78, 1404-1406.	2.9	57
89	A phase II study of bryostatatin 1 in metastatic malignant melanoma. <i>British Journal of Cancer</i> , 1998, 78, 1337-1341.	2.9	70
90	Phase I study of the mitomycin C analogue BMS-181174. <i>British Journal of Cancer</i> , 1998, 77, 2020-2027.	2.9	5

#	ARTICLE	IF	CITATIONS
91	A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. <i>Annals of Oncology</i> , 1997, 8, 294-296.	0.6	6
92	The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. <i>Clinical Oncology</i> , 1997, 9, 4-13.	0.6	13
93	Molecular approaches to diagnosis and management of ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 1997, 16, 81-107.	2.7	15
94	IMMUNOHISTOCHEMICAL EXPRESSION OF INHIBIN/ACTIVIN SUBUNITS IN EPITHELIAL AND GRANULOSA CELL TUMOURS OF THE OVARY. , 1997, 181, 413-418.		49
95	Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. , 1997, 18, 75-83.		42
96	An integrated genetic map of Chromosome 6. <i>Mammalian Genome</i> , 1996, 7, 157-159.	1.0	10
97	Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. , 1996, 67, 595-602.		65
98	Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. , 1996, 15, 223-233.		80
99	The genomic structure of discoidin receptor tyrosine kinase.. <i>Genome Research</i> , 1996, 6, 620-627.	2.4	28
100	H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. <i>Molecular Medicine</i> , 1996, 2, 189-203.	1.9	10
101	Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. <i>Clinical Cancer Research</i> , 1996, 2, 303-10.	3.2	14
102	The genetic analysis of ovarian cancer. <i>British Journal of Cancer</i> , 1995, 72, 521-527.	2.9	76
103	Inhibin as a marker for ovarian cancer. <i>British Journal of Cancer</i> , 1995, 71, 1046-1050.	2.9	106
104	AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 220-222.	1.5	9
105	Localization of an epithelial-specific receptor kinase (EDDR1) to chromosome 6q16. <i>Genomics</i> , 1995, 25, 584-587.	1.3	21
106	Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia. <i>Molecular Medicine</i> , 1995, 1, 161-71.	1.9	7
107	Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis.. <i>Journal of Clinical Pathology</i> , 1994, 47, 1077-1081.	1.0	30
108	Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. <i>Clinical Endocrinology</i> , 1994, 40, 717-723.	1.2	385

#	ARTICLE	IF	CITATIONS
109	Fluorescence in situ hybridization analysis using cosmid probes to define chromosome 6q abnormalities in ovarian carcinoma cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1994, 77, 99-105.	1.0	18
110	Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 1993, 68, 767-774.	2.9	38
111	Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. <i>Annals of Oncology</i> , 1993, 4, 385-392.	0.6	35
112	Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years. <i>British Journal of Cancer</i> , 1992, 65, 429-437.	2.9	9
113	Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital. <i>Annals of Oncology</i> , 1992, 3, 349-356.	0.6	2
114	Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. <i>British Journal of Cancer</i> , 1990, 62, 314-318.	2.9	26
115	Acute myeloid leukemia in elderly adults. <i>Hematological Oncology</i> , 1990, 8, 13-21.	0.8	34
116	Autoimmune Haemolytic Anaemia Associated with Malignant Peritoneal Mesothelioma. <i>Acta Clinica Belgica</i> , 1989, 44, 199-201.	0.5	10
117	Short-term therapy for acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 1988, 6, 218-226.	0.8	40
118	Identification of two normal bcr gene products in the cytoplasm. <i>Oncogene</i> , 1988, 3, 561-6.	2.6	16
119	Cytosine arabinoside in the management of recurrent leukaemia. <i>Hematological Oncology</i> , 1987, 5, 65-69.	0.8	6
120	Angio-immunoblastic lymphadenopathy: A clinical, immunological and molecular study. <i>British Journal of Cancer</i> , 1987, 55, 437-442.	2.9	26
121	Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. <i>Nature</i> , 1987, 329, 851-853.	13.7	101
122	Haematological classification of the chronic myeloid leukaemias. <i>Best Practice and Research: Clinical Haematology</i> , 1987, 1, 887-906.	1.1	61
123	EVA treatment for recurrent or unresponsive Hodgkin's disease. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 51-53.	1.1	42
124	Treatment of minimal residual disease in poor risk acute lymphoblastic leukaemia with high-dose cytosine arabinoside (ARA-C). <i>Leukemia Research</i> , 1986, 10, 90.	0.4	0
125	Neurotoxicity of High-Dose Cytosine Arabinoside. <i>Progress in Tumor Research</i> , 1985, 29, 177-182.	0.1	9
126	Central nervous system toxicity of high-dose cytosine arabinoside. <i>Seminars in Oncology</i> , 1985, 12, 227-32.	0.8	28